Amoy Diagnostics Co Ltd

Amoy Diagnostics maintains a strong liquidity position, with a current ratio of 11.53, indicating a high ability to meet short-term obligations. The company's liquidity_fpt score is elevated, supported by a free cash flow of 227.12 million CNY and a low debt-to-equity ratio of 0.05, suggesting minimal leverage risk. However, the risk assessment notes that net cash is negative after subtracting total debt, signaling potential liquidity constraints if cash flow deteriorates. Profitability metrics are robust, with a return on equity (ROE) of 17.57% and a return on assets (ROA) of 15.39%, both exceeding the industry median for medical equipment and diagnostics firms. The company's operating margin of 34.62% (calculated from operating income of 414.58 million CNY on revenue of 1.198 billion CNY) is also above the sector average, reflecting efficient cost management and pricing power. Geographically, Amoy Diagnostics is heavily concentrated in the Chinese domestic market, with no disclosed international revenue segments. This concentration increases exposure to local regulatory shifts and economic volatility, particularly in the healthcare sector. The company's revenue is derived from a single business model — diagnostic services and equipment — with no material diversification across product lines or customer bases. Growth expectations are positive, with analysts projecting a mean price target of 28.59 CNY, implying a 12.3% upside from the current share price. The company's revenue growth is expected to remain stable, supported by the expanding demand for diagnostic services in China. Capital expenditures were negative at -70.23 million CNY, indicating asset sales or reduced investment in physical infrastructure, which may signal a shift toward service-based expansion. Risk factors include the company's reliance on a single geographic market and the potential for regulatory changes in the healthcare sector. The risk assessment assigns a "medium" liquidity risk and "low" dilution risk, with no immediate pressure from share issuance or convertible debt. The company's capital structure is conservative, with long-term debt of 108.60 million CNY and total liabilities of 291.69 million CNY, representing only 12.4% of total assets. Recent events include strong analyst sentiment, with a mean recommendation of 1.80 (favoring buy) and no hold or sell ratings. The company has not disclosed any material recent filings or earnings transcripts that would suggest operational or strategic shifts.